Show simple item record

dc.contributor.authorAbraham, J
dc.contributor.authorVallier, L
dc.contributor.authorQian, W
dc.contributor.authorMachin, A
dc.contributor.authorGrybowicz, L
dc.contributor.authorThomas, S
dc.contributor.authorWeiss, M
dc.contributor.authorHarvey, C
dc.contributor.authorMcAdam, K
dc.contributor.authorHughes-Davies, L
dc.contributor.authorRoberts, A
dc.contributor.authorRoylance, R
dc.contributor.authorCopson, E
dc.contributor.authorPinilla, K
dc.contributor.authorArmstrong, Anne C
dc.contributor.authorProvenzano, E
dc.contributor.authorTischkowitz, M
dc.contributor.authorMcMurtry, E
dc.contributor.authorEarl, H
dc.date.accessioned2019-03-29T14:22:33Z
dc.date.available2019-03-29T14:22:33Z
dc.date.issued2018en
dc.identifier.citationAbraham J, Vallier A, Qian W, Machin A, Grybowicz L, Thomas S, et al. PARTNER: randomised, phase 2/3 trial evaluating safety & efficacy of adding olaparib to platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients. Br J Cancer. 2018;119(11):45.en
dc.identifier.urihttp://hdl.handle.net/10541/621686
dc.language.isoenen
dc.titlePARTNER: randomised, phase 2/3 trial evaluating safety & efficacy of adding olaparib to platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patientsen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentDept of oncology, The Christie NHS FT, Manchesteren
dc.identifier.journalBritish Journal of Canceren
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record